Price Target Update on Valeant Pharmaceuticals International (NYSE:VRX)

Valeant Pharmaceuticals International (NYSE:VRX) : The most positive equity analysts on Valeant Pharmaceuticals International (NYSE:VRX) expects the shares to touch $90, whereas, the least positive believes that the stock will trade at $11 in the short term. The company is covered by 12 Wall Street Brokerage Firms. The average price target for shares are $42.92 with an expected fluctuation of $21.18 from the mean.

Other Equity analysts have also commented on the company shares. Jefferies maintains their rating on the shares of Valeant Pharmaceuticals International (NYSE:VRX). The current rating of the shares is Buy. Equity Analysts at the Firm lowers the price target to $40 per share from $53 per share. The rating by the firm was issued on June 8, 2016.

Valeant Pharmaceuticals International (NYSE:VRX): stock turned positive on Thursday. Though the stock opened at $21.62, the bulls momentum made the stock top out at $22.3 level for the day. The stock recorded a low of $21.4 and closed the trading day at $22.25, in the green by 2.82%. The total traded volume for the day was 18,161,551. The stock had closed at $21.64 in the previous days trading.

The company shares have dropped -90.72% from its 1 Year high price. On Aug 6, 2015, the shares registered one year high at $263.81 and the one year low was seen on Jun 21, 2016. The 50-Day Moving Average price is $26.58 and the 200 Day Moving Average price is recorded at $58.93. On the companys insider trading activities, The Securities and Exchange Commission has divulged in a Form 4 filing that the CEO of Valeant Pharmaceuticals International, Inc., Papa Joseph C had purchased shares worth of $4,944,960 in a transaction dated on June 10, 2016. A total of 202,000 shares were purchased at a price of $24.48 per share. The information is based on open market trades at the market prices.Option exercises are not covered.

Valeant Pharmaceuticals International, Inc. is a specialty pharmaceutical and medical device company. The Company is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices), which are marketed directly or indirectly in over 100 countries. The Company operates through two segments: developed markets and emerging markets. The Companys developed markets segment consists of sales in the United States of pharmaceutical products, OTC products, and medical device products. The Companys Emerging Markets segment consists of branded generic pharmaceutical products and branded pharmaceuticals, OTC products, and medical device products.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.